WARSAW, Ind.--(BUSINESS WIRE)--Biomet Orthopedics, LLC, a global leader in the manufacture of orthopedic and biotechnology products, today announced the first clinical use of the Signature™ Patient-Specific glenoid instrumentation in the United States. The Signature™ Glenoid System was introduced in Europe in February 2013, and is used in conjunction with Biomet's Comprehensive® shoulder system, the market-leading shoulder replacement system in the United States.
“In addition to providing a time-efficient and user-friendly solution to consistently place the glenoid component, Signature™ provides the surgeon the ability to seamlessly choose between anatomic and reverse shoulder arthroplasty.”
Signature™ glenoid guides utilize CT data and a proprietary algorithm to match each patient's anatomy and facilitate proper positioning of the glenoid component. The preoperative planning tool allows surgeons to make any necessary adjustments required for each patient, including component size, inclination, and version, prior to surgery.
The Signature™ glenoid guide is the only device of its type that features a patent-pending dual trajectory, allowing surgeons to elect a reverse or total shoulder procedure intraoperatively.
“Signature™ is a major advance in shoulder arthroplasty,” stated Dr. John W. Sperling, M.D., orthopedic surgeon in Rochester, Minnesota, and a participant in the product development of the Signature™ Glenoid System. “In addition to providing a time-efficient and user-friendly solution to consistently place the glenoid component, Signature™ provides the surgeon the ability to seamlessly choose between anatomic and reverse shoulder arthroplasty.”
“Given the inherent exposure and orientation challenges in total shoulder arthroplasty, this technology is ideally suited for the shoulder,” stated Dr. Jason M. Hurst, M.D., orthopedic surgeon with Joint Implant Surgeons in New Albany, Ohio, and a participant in the product development of the Signature™ Glenoid System. “With my initial experiences with the Signature™ Glenoid System, the pre-operative plans were well replicated by the guides and very easy to use. I believe that this tool provides me with reliable implant positioning.”
“The combination of the Signature™ Patient-Specific Glenoid Guide and the new Comprehensive® Access cannulated instruments enables us to position the glenoid component optimally and to implant the component with ease and speed,” stated Simon Frostick, Professor of Orthopedics and surgeon at the Royal Liverpool University Hospital in Liverpool, UK, and a participant in the product development of the Signature™ Glenoid System.
The Signature™ Glenoid System complements Biomet’s Access Instrumentation for its Comprehensive® shoulder platform, which features patent-pending, four-step cannulated glenoid instrumentation.
The Signature™ Glenoid System is the latest addition to Biomet's portfolio of patient-specific instrumentation technology. The Signature™ Knee System has been used in over 80,000 surgeries since its introduction in 2007. Biomet also recently introduced Signature™ instrumentation for acetabular positioning in total hip replacement.
Biomet, Inc. (www.biomet.com) and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet’s product portfolio encompasses large joint reconstructive products, including orthopedic joint replacement devices, and bone cements and accessories; sports medicine, extremities and trauma products, including internal and external orthopedic fixation devices; spine and bone healing products, including spine hardware, spinal stimulation devices, and orthobiologics, as well as electrical bone growth stimulators; dental reconstructive products; and other products, including microfixation products and autologous therapies. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in approximately 90 countries.
*Signature Knee and Hip Technology are collaborative partnerships with Materialise, N.V.